首页> 外文期刊>Journal of Heterocyclic Chemistry: The International Journal of Heterocyclic Chemistry >NEW PROCESS FOR THE SYNTHESIS OF UP 269-6, A 1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A POTENT ORALLY ACTIVE ANGIOTENSIN II ANTAGONIST
【24h】

NEW PROCESS FOR THE SYNTHESIS OF UP 269-6, A 1,2,4-TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A POTENT ORALLY ACTIVE ANGIOTENSIN II ANTAGONIST

机译:合成269,1,2,4-三唑并[1,5-C]嘧啶衍生物作为强效口服活性血管紧张素II拮抗剂的新方法

获取原文
获取原文并翻译 | 示例
           

摘要

A new synthetic route to prepare the 2-hydroxy-5-methyl-7-n-propyl-8-[[2'-(1H-tetrazol-5-yl)biphenyl- 4-yl]methyl]-[1,2,4]triazolo[1,5-c]pyrimidine (UP 269-6, Ripisartan) is described. UP 269-6 is a non-peptide angiotensin II antagonist currently in phase II clinical trials for the treatment of hypertension and chronic heart failure. Its development needed a suitable process for industrial production. The laboratory scale synthesis was optimized and particularly two key steps: 4-hydrazinopyrimidine formation without isolation of the 4-chloro intermediate acid its cyclization into triazolo[1,5-c]pyrimidine derivative without isolation of the triazolo[4,3-c]pyrimidine isomer using urea in N-methylpyrrolidone at 160 degrees C. This cyclization process affords a new and efficient way to prepare directly 2-hydroxytriazolo[1 5-c]pyrimidine without isolation of the corresponding triazolo[4,3-c] pyrimidine. [References: 8]
机译:制备2-羟基-5-甲基-7-正丙基-8-[[2'-(1H-四唑-5-基)联苯-4-基]甲基]-[1,2]的新合成路线描述了,4]三唑并[1,5-c]嘧啶(UP 269-6,Ripisartan)。 UP 269-6是一种非肽类血管紧张素II拮抗剂,目前正处于II期临床试验中,用于治疗高血压和慢性心力衰竭。它的发展需要适合工业生产的工艺。优化了实验室规模的合成,尤其是两个关键步骤:在不分离4-氯中间酸的情况下形成4-肼基嘧啶,无需分离三唑并[4,3-c],将其环化成三唑并[1,5-c]嘧啶衍生物。嘧啶异构体,是在160℃下在N-甲基吡咯烷酮中使用脲的。这种环化过程提供了一种直接制备2-羟基三唑并[1 5-c]嘧啶的新有效方法,而无需分离相应的三唑并[4,3-c]嘧啶。 [参考:8]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号